85710:BORRELIA BURGDORFERI IgG and IgM ANTIBODIES

Print View Attached Docs:
85710:BORRELIA BURGDORFERI IgG and IgM ANTIBODIES
Alias Names: B. Burgdorferi / Lyme Disease
Methodology: Enzyme Immunoassay (EIA)
Edit Date: 12/29/2010
Performed: Tuesday-Saturday
Released: 24 hours after setup at PeaceHealth Laboratories’ reference lab.
CPT Code: 86618-90 x2
Specimen Collection Details
Collection: One 7.5 mL serum separator tube (SST).
Handling: Allow to clot, centrifuge and separate serum into a plastic vial. Refrigerate.
Stability: 7 days ambient, 14 days refrigerated, or 2 months frozen.
Standard Volume: 2 mL serum.
Minimum Volume: 0.5 mL serum.
Transport: Refrigerated.
Comments: Paired testing of acute and convalescent specimens is recommended. A Rapid Plasma Reagin (RPR) is performed at no charge on all specimens positive for Borrelia burgdorferi antibodies by enzyme immunoassay to exclude potential cross-reactions with syphilis.

Reference Range:
<.80 Index
Whole-cell sonicate (WCS) Borrelia burgdorferi antigens are utilized to measure both IgM and IgG antibody responses to B. burgdorferi in human serum, using an enzyme-immunoassay methodology (EIA). This test is used as a screen in a two-tier test algorithm proposed by the CDC for assessment of exposure to B. burgdorferi during early- and late-stage disease. For determination of early-stage Lyme disease (within the first 4 weeks of onset of erythema migrans), both IgM and IgG antibody detection should be evaluated. For late-stage Lyme disease (after 4 weeks of onset of erythema migrans), only IgG antibody detection should be evaluated. All IgM and IgG EIA positive results should be confirmed using the second tier immunoblot (IB) method.

PeaceHealth Laboratories